Pfizer Accounts Payable 2010-2025 | PFE

Pfizer accounts payable for the quarter ending June 30, 2025 were $5.166B, a 1.18% increase year-over-year.

  • Pfizer accounts payable for 2024 were $5.633B, a 16.05% decline from 2023.
  • Pfizer accounts payable for 2023 were $6.71B, a 1.45% decline from 2022.
  • Pfizer accounts payable for 2022 were $6.809B, a 22.07% increase from 2021.

Pfizer Accounts Payable 2010-2025 | PFE

  • Pfizer accounts payable for 2024 were $5.633B, a 16.05% decline from 2023.
  • Pfizer accounts payable for 2023 were $6.71B, a 1.45% decline from 2022.
  • Pfizer accounts payable for 2022 were $6.809B, a 22.07% increase from 2021.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$694.9B
Johnson & Johnson (JNJ)$425.8B
AbbVie (ABBV)$367.6B
Novartis AG (NVS)$268B
Roche Holding AG (RHHBY)$260.3B
Novo Nordisk (NVO)$252B
Merck (MRK)$210B
Sanofi (SNY)$123B
Bayer (BAYRY)$32.3B
Innoviva (INVA)$1.3B